Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
AssigneeBioNumerik Pharmaceuticals, Inc.
InventorFrederick H. Hausheer
Life of this patent
Estimating the term…
Abstract
Provided are pharmaceutical drugs for preventing or mitigating adverse actions associated with taxane antineoplastic drugs which are frequently and widely used in cancer chemotherapy, and pharmaceutical compositions which allow us to shorten the duration of treatment with taxane antineoplastic agents and/or to repeat the taxane treatment course more times, as well as drugs suitable for the therapeutic schedules.
Claims51
A method for treating a patient having breast cancer, ovarian cancer, lung cancer, bladder cancer, or adenocarcinoma, the method, comprising:
- administering a course of therapy to the patient comprising a first composition comprising a therapeutically effective amount of an antineoplastic agent and a second composition selected from the group consisting of compositions comprising 2,2′-dithiobis ethane sulfonate in an amount ranging from 4.1 to 41.0 g/m2, 2,2′-dithiobis ethane sulfonate in an amount ranging from 12.3 g/m2 to 27.6 g/m2, and 2,2′-dithiobis ethane sulfonate in an amount of 18.4 g/m2;
- repeating the course of therapy from at least once a day to at least once every 2.5 weeks,
- wherein (a) the amount of antineoplastic agent administered in conjunction with the second composition is greater than the amount administered without the second composition and/or (b) the duration of time between courses of therapy administered with said antineoplastic agent and the second composition is shorter than the duration of time between courses of therapy with the antineoplastic agent alone, and further wherein toxicity of said antineoplastic agent is mitigated consequent to the administration of said antineoplastic agent.
A method of mitigating neurotoxicity in a patient undergoing a treatment for breast cancer, ovarian cancer, lung cancer, bladder cancer, or adenocarcinoma, including courses of therapy with an antineoplastic agent, the method comprising administering to the patient a composition comprising from 12.3 g/m2 to 27.6 g/m2 of 2,2′-dithio-bis-ethane sulfonate following or at about the same time as administration of the antineoplastic agent, wherein the course of treatment is administered more frequently than once every three weeks and whereby neurotoxicity associated with administration of an antineoplastic agent is mitigated.
A method for increasing tolerance to side effects of taxane antineoplastic agents in a patient having breast cancer, ovarian cancer, lung cancer, bladder cancer, or adenocarcinoma, by administering to the patient a composition selected from the group consisting of compositions comprising from 4.1 to 41.0 g/m2 of 2,2′-dithiobis ethane sulfonate, from 12.3 g/m2 to 27.6 g/m2 of 2,2′-dithiobis ethane sulfonate, and comprising 18.4 g/m2 of 2,2′-dithiobis ethane sulfonate prior to, after, or at about the same time as the administration of the antineoplastic agent, wherein tolerance to the side effects of the antineoplastic agent is increased.
A method for shortening the duration of treatment with a antineoplastic agent in a patient having breast cancer, ovarian cancer, lung cancer, bladder cancer, or adenocarcinoma, said method comprising administering to the patient a composition selected from the group consisting of compositions comprising from 4.1 to 41.0 g/m2 of 2,2′-dithiobis ethane sulfonate, from 12.3 g/m2 to 27.6 g/m2 of 2,2′-dithiobis ethane sulfonate, and comprising 18.4 g/m2 of 2,2′-dithiobis ethane sulfonate prior to or at about the same time as administration of the antineoplastic agent, whereby the duration of treatment of the patient with the antineoplastic agent is shortened.
A method for treating a patient having breast cancer, ovarian cancer, lung cancer, bladder cancer, or adenocarcinoma, comprising:
- administering a course of therapy to the patient comprising a first composition comprising a therapeutically effective amount of an antineoplastic agent and a composition comprising 2,2′-dithiobis ethane sulfonate in an amount selected from about 4.1, 12.3, 27.6, 18.4 and about 41.0 g/m2;
- repeating the course of therapy from at least once a day to at least once every 2.5 weeks,
- wherein (a) the amount of antineoplastic agent administered in conjunction with the second composition is greater than the amount administered without the second composition and/or (b) the duration of time between courses of therapy administered with a antineoplastic agent and the second composition is shorter than the duration of time between courses of therapy with the antineoplastic agent alone.
Dependencies are inferred from the claim text.